BCYC

Bicycle Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United Kingdom

Next Earnings Date

05/07/26

Business Summary

Bicycle Therapeutics is a clinical-stage biotechnology company developing targeted therapeutics using its proprietary bicyclic peptide platform. The firm generates value by designing highly specific molecules intended to bind disease targets with precision, aiming to improve efficacy while limiting systemic toxicity. Cash generation is dependent on advancing candidates through clinical milestones, securing partnerships, and eventually achieving regulatory approval that can unlock product sales or licensing revenue. Its moat rests on intellectual property around its peptide technology and the scientific know-how required to translate that platform into viable drug candidates, rather than on current cash flow strength.

VALUATION

P/E

-

Market Cap ($M USD)

$344

Forward P/E

-

PEG

-

PRICE TO SALES

4.7

PRICE TO BOOK

0.6

EV / EBITDA

1.3

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$3.16

Next Year EPS Growth Estimate

-$1.90

Next Year Revenue Growth Estimate

-9.70%

Return on Equity (ROE)

-35.90%

Operating Margin

-341.30%

Debt-to-Equity

0

Piotroski F-Score

1

Altman Z-Score

0.2

Return on Invested Capital (ROIC)

-33.60%%

Current Ratio

12

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $344M market cap with a Price/Sales of 4.7 and Price/Book of 0.6, BCYC screens optically cheap on asset value but structurally distressed on fundamentals. The absence of a P/E and Forward P/E combined with an EPS Next Year estimate of -$3.16 signals persistent losses rather than a near-term earnings inflection. An Altman Z-Score of 0.2 is deep in distress territory, and a Piotroski F-Score of 1 confirms deteriorating financial quality. This is not a misunderstood growth compounder; it is a balance-sheet-stressed biotech priced as a speculative turnaround with meaningful insolvency risk embedded.

AI Exposure / Tech Reliance

As a Biotechnology company, BCYC operates in a research-driven sector where AI-enhanced drug discovery and data modeling are becoming standard competitive tools. The industry’s increasing reliance on computational biology and precision targeting could theoretically improve development efficiency. However, there is nothing in the provided metrics that demonstrates BCYC is currently translating technological leverage into financial performance.

The Bull Case

A deep value investor could argue that a Price/Book of 0.6 implies the market is valuing the company below its accounting equity, suggesting potential asset-based downside protection. The Current Ratio of 12 indicates substantial short-term liquidity, which is critical for a cash-burning biotech navigating clinical development cycles. Despite a weak Piotroski F-Score of 1 and negative ROIC of -33.60%, a contrarian might view the depressed valuation, $344M market cap, and institutional ownership of $12.55 as signs that expectations are already washed out. If operating performance stabilizes even modestly from a -35.90% operating margin base, equity re-rating could be sharp given how low the bar currently sits.

The Bear Case

The bear case is overwhelming. Debt/Equity of -341.30% signals a severely impaired capital structure, while ROE of -9.70% and ROIC of -33.60% confirm that capital is being destroyed, not compounded. Sales Growth Next Year of -$1.90 and EPS Next Year of -$3.16 imply continued deterioration rather than recovery. An Altman Z-Score of 0.2 places the company in extreme financial distress territory, and a Piotroski F-Score of 1 reinforces that virtually every core financial health signal is flashing red. This is a structurally unprofitable enterprise with negative operating margin, no dividend support, and no valuation anchor beyond speculative pipeline hope.

Market Sentiment & Smart Money

Short Interest %

5.60%

Analyst Consensus

1.92

Average Analyst Price Target

$12.55

Institutional Ownership %

75.80%

1-Year Beta

1.64

Insider Buying % (6 Mo)

4.40%%

Distance to 52-Week High

51.70%%

Distance to 52-Week Low

116.50%%